Jubilant Pharmova Limited
Theleme India increased its stake in Jubilant Pharmova Limited from 1.69% to 2.02%, purchasing 5,19,129 shares.
An integrated global pharmaceuticals company, Jubilant Pharmova operates across three core business segments: pharmaceuticals, contract research and development services, and proprietary novel drugs. The company serves domestic and international markets through its diversified portfolio and specialized capabilities in drug development and manufacturing. It combines vertically integrated operations with expertise in custom synthesis and advanced pharmaceutical formulations to address healthcare needs across multiple therapeutic areas.
India equity vehicle of Theleme Partners, a London-based concentrated hedge fund founded in 2009 by Patrick Degorce (founding partner of TCI under Chris Hohn, ex-Merrill Lynch and Lehman). Theleme runs around USD 2 bn in 13F securities across a high-conviction global long book that frequently includes large Indian positions.